Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs

Pharmacogenomics

Volumn 4, Issue 4, 2003, Pages 397-410

  Sakaeda, Toshiyuki ^a   Nakamura, Tsutomu ^a   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Apoptosis; Disease risk; Expression; Function; Haplotype analysis; Immunological reaction; MDR1; P glycoprotein; Pharmacodynamics; Pharmacokinetics; Single nucleotide polymorphism (SNP)

Indexed keywords

ABC TRANSPORTER; ACETYLDIGOXIN; AMINO ACID; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DACTINOMYCIN; DAUNORUBICIN; DIGITOXIN; DIGOXIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; IRINOTECAN; MEMBRANE PROTEIN; METILDIGOXIN; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEINASE INHIBITOR; QUINIDINE; TENIPOSIDE; TOPOTECAN; TOXIC SUBSTANCE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

AMINO ACID SUBSTITUTION; CLINICAL STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG STRUCTURE; DUODENUM; ENTERITIS; EPITHELIUM TUMOR; ETHNIC DIFFERENCE; EXON; FOOD DRUG INTERACTION; GENE FREQUENCY; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; GRAPE JUICE; HAPLOTYPE; HUMAN; KIDNEY EPITHELIUM; METABOLITE; MULTIDRUG RESISTANCE; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

VITIS SP.;

EID: 0038106665     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.4.397.22747     Document Type: Review

References (97)

1. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455(1), 152-162 (1976).
2. Ueda K, Clark DP, Chen C, Roninson IB, Gottesman MM, Pastan I: The human multidrug resistance (mdr1) gene. J. Biol. Chem. 262(2), 505-508 (1987).
3. Chen C, Chin JE, Ueda K et al.: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47(3), 381-389 (1986).
4. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 84(9), 3004-3008 (1987).
5. Chen C, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 265(1), 506-514 (1990).
6. Rosenberg MF, Callaghan R, Ford RC, Higgins CF: Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem. 272(16), 10685-10694 (1997).
7. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug trasnporter. Ann. Rev. Pharmacol. Toxicol. 39, 361-398 (1999).
8. Higgins CF, Gottesman MM: Is the multidrug transporter a flippase? Trends Biochem. Sci. 17(1), 18-21 (1992).
9. van Helvoort A, Smith AJ, Sprong H et al.: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87(3), 507-517 (1996).
10. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 84(21), 7735-7738 (1987).
11. Kusuhara H, Suzuki H, Sugiyama Y: The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 97(9), 1025-1040 (1998).
12. Tanigawara Y: Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 22(1), 137-140 (2000).
13. Borst P, Schinkel AH, Smit JJM et al.: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmac. Ther. 60(2), 289-299 (1993).
14. Watkins PB: The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27(2-3), 161-170 (1997).
15. Hyde SC, Emsley P, Hartshorn MJ et al.: Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346(6282), 362-365 (1990).
16. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11(7), 1156-1166 (2001).
17. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42(7), 1007-1017 (2001).
18. Matheny CJ, Lamb MW, Brouwer KLR, Pollack GM: Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21(7), 778-796 (2001).
19. Rodriguez I, Abernethy DR, Woosley RL: P-glycoprotein in clinical cardiology. Circulation 99(4), 472-474 (1999).
20. Hunter J, Hirst BH: Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 25, 129-157 (1997).
21. Stouch TR, Gudmundsson O: Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 54(3), 315-328 (2002).
22. Fromm MF, Eichelbaum M: The pharmacogenomics of human P-glycoprotein. In: Pharmacogenomics. The Search for Individualized Therapies. Licinio J, Wong ML (Eds), Wiley-VCH Verlag GmbH, Weinheim, Germany, 159-178 (2002).
23. Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13(3), 129-134 (1995).
24. Wacher VJ, Silverman JA, Zhang Y, Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87(11), 1322-1330 (1998).
25. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, Wood AJJ: P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res. 59(16), 3944-3948 (1999).
26. Kim RB, Wandel C, Leake B et al.: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16(3), 408-414 (1999).
27. Tran CDH, Timmins P, Conway BR, Irwin WJ: Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells. J. Pharm. Sci. 91(1), 117-128 (2002).
28. Sakaeda T, Takara K, Kakumoto M et al.: Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J. Pharm. Pharmacol. 54(3), 419-423 (2002).
29. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 70(13), 1491-1500 (2002).
30. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 77(3), 142-144 (1987).
31. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB: Structure and expression of the human MDR1 (P-glycoprotein) gene family. Mol. Cell Biol. 9(9), 3808-3820 (1989).
32. 185 with an altered pattern of multidrug resistance. Biochem. Biophys. Res. Commun. 162(1), 224-231 (1989).
33. Stein U, Walther W, Wunderlich V: Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur. J. Cancer 30A(10), 1541-1545 (1994).
34. Mickley LA, Lee JS, Weng Z et al.: Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91(5), 1749-1756 (1998).
35. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97(7), 3473-3478 (2000).
36. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsube K: Polymorphism of the ABC transporter genes, MDR1, MPP1 and MRP2/cMOAT in healthy Japanese subjects. Pharmacogenetics 11(2), 175-184 (2001).
37. Cascorbi I, Gerloff T, Johne A et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69(3), 169-174 (2001).
38. Tanabe M, Ieiri I, Nagata N et al.: Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297(3), 1137-1143 (2001).
39. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
40. Ameyaw MM, Regateiro F, Liu T et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11(3), 217-221 (2001).
41. Schaeffeler E, Eichelbaum U, Brinkmann U et al.: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358(9279), 383-384 (2001).
42. Sakaeda T, Nakamura T, Horinouchi M et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18(10), 1400-1404 (2001).
43. Bernal ML, Sinues B, Fanlo A, Mayayo E: Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 25(1), 107-111 (2003).
44. Horinouchi M, Sakaeda T, Nakamura T et al.: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: Functional relevance to pharmacokinetics of digoxin. Pharm. Res. 19(10), 1581-1585 (2002).
45. Furuno T, Landi MT, Ceroni M et al.: Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12(7), 529-534 (2002).
46. Zheng HX, Webber S, Zeevi A et al.: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum. Immunol. 63(9), 765-770 (2002).
47. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2), 89-95 (2003).
48. Siddiqui A, Kerb R, Weale ME et al.: Assiciation of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442-1448 (2003).
49. Greiner B, Eichelbaum M, Fritz P et al.: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104(2), 147-153 (1999).
50. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66(4), 338-345 (1999).
51. + natural killer cells. Pharmacogenetics 11(4), 293-298 (2001).
52. Nakamura T, Sakaeda T, Horinouchi M et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71(4), 297-303 (2002).
53. Goto M, Masuda S, Saito H et al.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12(6), 451-457 (2002).
54. Siegmund W, Ludwig K, Giessmann T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72(5), 572-583 (2002).
55. C3435T polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13(7 , 1847-1854 (2002).
56. Illmer T, Schuler US, Thieda C et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62(17), 4955-4962 (2002).
57. Moriya Y, Nakamura T, Horinouchi M et al.: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25(10), 1356-1359 (2002).
58. Synold TW, Dussault I, Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7(5), 584-590 (2001).
59. Kimchi-Sarfaty C, Gribar JJ, Gottesmann MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62(1), 1-6 (2002).
60. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65(11), 1843-1852 (2003).
61. Becquemont L, Verstuyft C, Kerb R et al.: Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70(4), 311-316 (2001).
62. Verstuyft C, Strabach S, Morabet HE et al.: Dipyridamole enhances digoxin bioavailabiliry via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73(1), 51-60 (2003).
63. Drescher S, Schaeffeler E, Hitzl M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53(5), 526-534 (2002).
64. Gerloff T, Schaefer M, Johne A et al.: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 54(6), 610-616 (2002).
65. Kurata Y, Ieiri I, Kimura M et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72(2), 209-219 (2002).
66. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359(9300), 30-36 (2002).
67. Johne A, Köpke K, Gerloff T et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72(5), 584-594 (2002).
68. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47(6), 1048-1052 (2001).
69. Min DI, Ellingrod VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 24(3), 400-404 (2002).
70. Gob BC, Lee SC, Wang LZ et al.: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20(17), 3683-3690 (2002).
71. Morita Y, Sakaeda T, Horinouchi M et al.: MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res. 20(4), 552-556 (2003).
72. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem. Biophys. Res. Commun. 292(1), 190-194 (2002).
73. Ueda K, Yoshida A, Amachi T: Recent progress in P-glycoprotein research. Anti-Cancer Drug Des. 14(2), 115-121 (1999).
74. Ramachandran M, Melnick SJ: Multidrug resistance in human tumors - molecular diagnosis and clinical significance. Mol. Diagn. 4(2), 81-94 (1999).
75. Persidis A: Cancer multidrug resistance. Nat. Biotechnol. 17(1), 94-95 (1999).
76. Szabo D, Keyzer H, Kaiser HE, Molnar J: Reversal of multidrug resistance of tumor cells. Anti-Cancer Res. 20(6B), 4261-4274 (2000).
77. Bradshaw DM, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 16(11), 3674-3690 (1998).
78. Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer 32A(6), 991-1001 (1996).
79. Sarkadi B, Müller M: Search for specific inhibitors of multidrug resistance in cancer. Semin. Cancer Biol. 8(3), 171-182 (1997).
80. Schwab M, Schaeffeler E, Marx C et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124(1), 26-33 (2003).
81. Panwala CM, Jones JC, Viney JL: A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161(10), 5733-5744 (1998).
82. Maggio-Price L, Shows D, Waggie K et al.: Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am. J. Pathol. 160(2), 739-751 (2002).
83. Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug trnsporter P-glycoprotein? Trends Biochem. Sci. 25(1), 1-6 (2000).
84. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ: A role for P-glycoprotein in regulating cell death. Leukemia Lymphoma 38(1-2), 1-11 (2000).
85. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25(11), 1391-1400 (2002).
86. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA 95(12), 7024-7029 (1998).
87. Johnstone RW, Cretney E, Smyth MJ: P-Glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood, 93(3), 1075-1085 (1999).
88. Sakaeda T, Nakamura T, Hirai M et al.: MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm. Res. 19(9), 1323-1329 (2002).
89. Lee CGL, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesman MM: Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14(3), 516-522 (2000).
90. Oudard S, Levalois C, Andrieu JM et al.: Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anti-Cancer Res. 22(1A), 121-128 (2002).
91. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously downregulates steroid xenobiotic receptor (SXR) mRNA. Biochem. Biophys. Res. Commun. 306(1), 116-120 (2003).
92. Zhang J, Kuehl P, Green ED et al.: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11(7), 555-572 (2001).
93. Hustert E, Zibat A, Presecan-Siedel E et al.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29(11), 1454-1459 (2001).
94. Gwee PC, Tang K, Chua JMZ, Lee EJD, Chong SS, Lee CGL: Simulatneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. Clin. Chem. 49(4), 672-676 (2003).
95. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
96. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 6(2), 71-84 (2003).
97. Tirona RG, Kim RB: Pharmacogenomics of drug transporters. In: Pharmacogenomics. The Search for Individualized Therapies. Licinio J, Wong ML (Eds), Wiley-VCH Verlag GmbH, Weinheim, Germany, 179-213 (2002).